Phase III, randomised, double-blind study.
RA patients randomised (1:1) to receive reference infliximab or Flixabi™. Patients receiving IFX who completed 54 weeks and were willing to participate in the extension study were rerandomised to either switch to Flixabi™ or continue receiving IFX